MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

Accounts receivable, net-$19,315K (-266.88%↓ Y/Y)Prepaid expenses-$17,105K (-218.38%↓ Y/Y)Accounts payable$15,696K (15.39%↑ Y/Y)Other accruedliabilities$13,297K Proceeds from maturitiesof marketable...$44,349K (-73.95%↓ Y/Y)Proceeds from exercise ofstock options$1,864K (-29.45%↓ Y/Y)Proceeds from sale ofcommon stock under...$1,438K (30.61%↑ Y/Y)Stock-based compensation$13,289K (-12.36%↓ Y/Y)Accrued payroll andbenefits$3,358K (179.72%↑ Y/Y)Depreciation$760K (90.00%↑ Y/Y)Amortization of intangibleassets$240K (-50.00%↓ Y/Y)Inventory-$198K (-115.81%↓ Y/Y)Loss on disposal ofproperty and equipment-$183K Amortization of debt-relatedcosts$166K (-41.75%↓ Y/Y)Non-cash lease expense$92K (-71.52%↓ Y/Y)Other non-currentassets-$55K (75.77%↑ Y/Y)Net cash provided by(used in) operating...$61,223K (222.35%↑ Y/Y)Net cash used ininvesting activities$37,878K (143.72%↑ Y/Y)Net cash provided byfinancing activities$3,302K (-97.62%↓ Y/Y)Canceled cashflow$22,545K Canceled cashflow$6,471K Net increase incash, cash...$102,403K (5495.79%↑ Y/Y)Net loss-$18,551K (59.19%↑ Y/Y)Gain on exchange oflong-term investments$2,812K Netamortization/accretion of marketable...$762K (-74.79%↓ Y/Y)Other receivables$396K (-34.87%↓ Y/Y)Unrealized (gain) loss fromtransactions denominated in a...$24K (192.31%↑ Y/Y)Purchases of property andequipment$4,069K (155.75%↑ Y/Y)Purchases of marketablesecurities$2,402K (-99.06%↓ Y/Y)
Cash Flow

Tarsus Pharmaceuticals, Inc. (TARS)

Tarsus Pharmaceuticals, Inc. (TARS)

source: myfinsight.com